Alexion Pharmaceuticals, Inc. (ALXN) Receives Outperform Rating from Leerink Swann

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)‘s stock had its “outperform” rating reaffirmed by Leerink Swann in a report released on Wednesday. They presently have a $182.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $170.00. Leerink Swann’s target price points to a potential upside of 26.33% from the stock’s current price. The analysts noted that the move was a valuation call.

Several other equities analysts have also issued reports on ALXN. J P Morgan Chase & Co lowered Alexion Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Tuesday, May 23rd. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 23rd. Barclays PLC reiterated an “overweight” rating and issued a $155.00 price target on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Stifel Nicolaus reiterated a “buy” rating and issued a $157.00 price target on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $158.00 price target on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Five equities research analysts have rated the stock with a hold rating, twenty have given a buy rating and three have issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $157.55.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 0.05% during trading on Wednesday, reaching $144.14. The company’s stock had a trading volume of 294,762 shares. Alexion Pharmaceuticals has a 1-year low of $96.18 and a 1-year high of $149.34. The company’s 50 day moving average price is $137.20 and its 200-day moving average price is $124.25. The stock has a market cap of $32.17 billion, a P/E ratio of 62.51 and a beta of 1.40.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The company had revenue of $912.00 million for the quarter, compared to analyst estimates of $846.15 million. During the same quarter last year, the company posted $1.13 EPS. The company’s revenue for the quarter was up 21.1% compared to the same quarter last year. Equities analysts forecast that Alexion Pharmaceuticals will post $5.61 earnings per share for the current fiscal year.

WARNING: This report was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://stocknewstimes.com/2017/09/13/alexion-pharmaceuticals-inc-alxn-rating-reiterated-by-leerink-swann.html.

In other news, EVP Julie O’neill sold 11,160 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $140.00, for a total value of $1,562,400.00. Following the completion of the transaction, the executive vice president now directly owns 26,704 shares of the company’s stock, valued at approximately $3,738,560. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Ann M. Veneman sold 700 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $137.74, for a total value of $96,418.00. Following the completion of the transaction, the director now directly owns 6,315 shares of the company’s stock, valued at $869,828.10. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,070 shares of company stock valued at $2,416,869. Corporate insiders own 4.35% of the company’s stock.

Several hedge funds have recently bought and sold shares of ALXN. Guardian Life Insurance Co. of America raised its position in shares of Alexion Pharmaceuticals by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 6 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of Alexion Pharmaceuticals in the 1st quarter worth about $111,000. Fiduciary Trust Co. bought a new position in shares of Alexion Pharmaceuticals in the 2nd quarter worth about $111,000. Huntington National Bank raised its position in shares of Alexion Pharmaceuticals by 1,084.6% in the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 987 shares in the last quarter. Finally, Penserra Capital Management LLC raised its position in shares of Alexion Pharmaceuticals by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 144 shares in the last quarter. 94.26% of the stock is owned by hedge funds and other institutional investors.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply